Patients on ECMO exhibit a range of hemostatic changes including consumption of coagulation factors, thrombocytopenia, altered von Willebrand factor (vWF) multimers and platelet dysfunction1 and reductions in anti-thrombin levels2. The gene discussed is VWF; the disease is Thrombocytopenia.